1887

Abstract

Hepatitis C virus (HCV) is a leading cause of chronic viral hepatitis, but an effective vaccine is still not available to prevent infection. Use of neutralizing antibodies could be a potential therapeutic option. In this study, the presence of anti-HCV antibodies in HCV-infected patients was assessed from 50 patients and the presence of neutralizing antibodies was examined using ‘hepatitis C virus-like particles’. Antibodies from two samples exhibited significant inhibitory activity, suggesting that these may neutralize viral infection. Antigenic determinants generating the neutralizing antibodies from these two samples were delineated by epitope mapping using the core, E1 and E2 regions and a stretch of 45 amino acid peptide (E2C45) derived from the C-terminal region of HCV-E2 protein (aa 634–679) was designed. Results suggest that this hitherto uncharacterized region has the potential to generate neutralizing antibodies against HCV and thus be effective in preventing virus entry into liver cells. Computational analysis of the structure of the modelled peptide (E2C45) suggested high conformational entropy for this region. Furthermore, E2C45 peptide-generated antibodies could block virus entry and monoclonal antibodies generated against this peptide could also significantly reduce virus replication in a cell culture system. It is possible that the inhibition could be partly due to a conformational alteration of the CD81-binding region, preventing virus attachment to liver cells. In conclusion, this work focused on the discovery of a novel epitope at the C terminus of E2 that induces potent neutralizing antibodies in HCV-infected patients.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000735
2017-05-08
2019-12-08
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/5/962.html?itemId=/content/journal/jgv/10.1099/jgv.0.000735&mimeType=html&fmt=ahah

References

  1. Baugh JM, Garcia-Rivera JA, Gallay PA. Host-targeting agents in the treatment of hepatitis C: a beginning and an end?. Antiviral Res 2013;100:555–561 [CrossRef][PubMed]
    [Google Scholar]
  2. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392–420 [CrossRef][PubMed]
    [Google Scholar]
  3. Christdas J, Sivakumar J, David J, Daniel HD, Raghuraman S et al. Genotypes of hepatitis C virus in the Indian sub-continent: a decade-long experience from a tertiary care hospital in South India. Indian J Med Microbiol 2013;31:349–353 [CrossRef][PubMed]
    [Google Scholar]
  4. Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E et al. Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design. Viruses 2015;7:3995–4046 [CrossRef][PubMed]
    [Google Scholar]
  5. Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S et al. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol 2012;86:11558–11566 [CrossRef][PubMed]
    [Google Scholar]
  6. Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006;80:5308–5320 [CrossRef][PubMed]
    [Google Scholar]
  7. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003;278:41003–41012 [CrossRef][PubMed]
    [Google Scholar]
  8. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766–12771 [CrossRef][PubMed]
    [Google Scholar]
  9. Monazahian M, Böhme I, Bonk S, Koch A, Scholz C et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999;57:223–229 [CrossRef][PubMed]
    [Google Scholar]
  10. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo J 2002;21:5017–5025 [CrossRef][PubMed]
    [Google Scholar]
  11. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F et al. Binding of hepatitis C virus to CD81. Science 1998;282:938–941 [CrossRef][PubMed]
    [Google Scholar]
  12. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801–805 [CrossRef][PubMed]
    [Google Scholar]
  13. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882–886 [CrossRef][PubMed]
    [Google Scholar]
  14. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011;17:589–595 [CrossRef][PubMed]
    [Google Scholar]
  15. Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 2013;110:10777–10782 [CrossRef][PubMed]
    [Google Scholar]
  16. Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M et al. Identification of the niemann-pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281–285 [CrossRef][PubMed]
    [Google Scholar]
  17. Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M et al. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol 2007;81:5036–5045 [CrossRef][PubMed]
    [Google Scholar]
  18. Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF et al. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors. J Virol 2014;88:10584–10597 [CrossRef][PubMed]
    [Google Scholar]
  19. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–2416 [CrossRef][PubMed]
    [Google Scholar]
  20. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–1206 [CrossRef][PubMed]
    [Google Scholar]
  21. Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014;95:78–88 [CrossRef][PubMed]
    [Google Scholar]
  22. Edwards VC, Tarr AW, Urbanowicz RA, Ball JK. The role of neutralizing antibodies in hepatitis C virus infection. J Gen Virol 2012;93:1–19 [CrossRef][PubMed]
    [Google Scholar]
  23. Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M et al. Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol 2010;84:34–43 [CrossRef][PubMed]
    [Google Scholar]
  24. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623–626 [CrossRef][PubMed]
    [Google Scholar]
  25. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005;102:9294–9299 [CrossRef][PubMed]
    [Google Scholar]
  26. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K et al. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007;25:7773–7784 [CrossRef][PubMed]
    [Google Scholar]
  27. Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB et al. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. Hepatology 2013;58:1587–1597 [CrossRef][PubMed]
    [Google Scholar]
  28. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002;2:706–713 [CrossRef][PubMed]
    [Google Scholar]
  29. Tabll A, Abbas AT, El-Kafrawy S, Wahid A. Monoclonal antibodies: principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. World J Hepatol 2015;7:2369–2383 [CrossRef][PubMed]
    [Google Scholar]
  30. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011;54:1273–1285 [CrossRef][PubMed]
    [Google Scholar]
  31. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 2005;79:11095–11104 [CrossRef][PubMed]
    [Google Scholar]
  32. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 2012;109:6205–6210 [CrossRef][PubMed]
    [Google Scholar]
  33. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014;509:381–384 [CrossRef][PubMed]
    [Google Scholar]
  34. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013;342:1090–1094 [CrossRef]
    [Google Scholar]
  35. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 2004;32:W526–W531 [CrossRef][PubMed]
    [Google Scholar]
  36. Zhang Y, Skolnick J. TM-align: a protein structure alignment algorithm based on the TM-score. Nucleic Acids Res 2005;33:2302–2309 [CrossRef][PubMed]
    [Google Scholar]
  37. McGuffin LJ, Bryson K, Jones DT. The PSIPRED protein structure prediction server. Bioinformatics 2000;16:404–405 [CrossRef][PubMed]
    [Google Scholar]
  38. Bose M, Mullick R, das S, das S, Karande AA. Combination of neutralizing monoclonal antibodies against hepatitis C virus E2 protein effectively blocks virus infection. Virus Res 2016;224:46–57 [CrossRef][PubMed]
    [Google Scholar]
  39. Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013;207:S7–S12 [CrossRef][PubMed]
    [Google Scholar]
  40. Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 2014;105:100–111 [CrossRef][PubMed]
    [Google Scholar]
  41. Wahid A, Dubuisson J. Virus-neutralizing antibodies to hepatitis C virus. J Viral Hepat 2013;20:369–376 [CrossRef][PubMed]
    [Google Scholar]
  42. Fafi-Kremer S, Fauvelle C, Felmlee DJ, Zeisel MB, Lepiller Q et al. Neutralizing antibodies and pathogenesis of hepatitis C virus infection. Viruses 2012;4:2016–2030 [CrossRef][PubMed]
    [Google Scholar]
  43. Vieyres G, Dubuisson J, Patel AH. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J Gen Virol 2011;92:494–506 [CrossRef][PubMed]
    [Google Scholar]
  44. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA 2009;106:7537–7541 [CrossRef][PubMed]
    [Google Scholar]
  45. Das S, Shetty RK, Kumar A, Shridharan RN, Tatineni R et al. Monoclonal antibodies against hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system. PLoS One 2013;8:e53619 [CrossRef][PubMed]
    [Google Scholar]
  46. Kumar A, das S, Mullick R, Lahiri P, Tatineni R et al. Immune responses against hepatitis C virus genotype 3a virus-like particles in mice: a novel VLP prime-adenovirus boost strategy. Vaccine 2016;34:1115–1125 [CrossRef][PubMed]
    [Google Scholar]
  47. Lohmann V, Korner F, Koch J, Herian U, Theilmann L et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110–113[CrossRef]
    [Google Scholar]
  48. Kato T, Date T, Murayama A, Morikawa K, Akazawa D et al. Cell culture and infection system for hepatitis C virus. Nat Protoc 2006;1:2334–2339 [CrossRef][PubMed]
    [Google Scholar]
  49. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791–796 [CrossRef][PubMed]
    [Google Scholar]
  50. Sekine-Osajima Y, Sakamoto N, Mishima K, Nakagawa M, Itsui Y et al. Development of plaque assays for hepatitis C virus-JFH1 strain and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology 2008;371:71–85 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000735
Loading
/content/journal/jgv/10.1099/jgv.0.000735
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error